✨ Free AI Report
Instil Bio, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Instil Bio, Inc.
Company Research

Instil Bio, Inc.: Business Overview, Financials & Competitive Analysis

Instil Bio, Inc. scores 3/10 on the AskCyborg Cyborg Score (Weak). Early-stage TIL cell therapy company with promising platform but severe near-term cash burn risk and market execution challenges. The company is currently unprofitable and not forecast to become profitable over the next 3 years. The stock has significantly underperformed both its industry and the broader market over the past.

What is Instil Bio, Inc.'s industry? Instil Bio, Inc. (instilbio.com) operates in Biopharmaceutical - Immunotherapy/Cell Therapy. AskCyborg classifies Instil Bio, Inc. under Biopharmaceutical - Immunotherapy/Cell Therapy in its company registry.

Instil Bio is a clinical-stage biopharmaceutical company developing a pipeline of cell therapies, specifically autologous tumor infiltrating lymphocyte (TIL) therapies for cancer treatment. The company was incorporate...

3/ 10Weak

Cyborg Score thesis

Early-stage TIL cell therapy company with promising platform but severe near-term cash burn risk and market execution...

Read the full analyst-debate transcript →
Industry Biopharmaceutical - Immunotherapy/Cell Therapy
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Instil Bio, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Instil Bio, Inc.

AskCyborg analysts argue the bull and bear cases for Instil Bio, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Instil Bio, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Instil Bio, Inc. Overview

Pro stress-test →

Instil Bio is a clinical-stage biopharmaceutical company developing a pipeline of cell therapies, specifically autologous tumor infiltrating lymphocyte (TIL) therapies for cancer treatment. The company was incorporated in 2018 and is headquartered in Dallas, Texas.

Strategic Profile

Pro stress-test →

The company focuses on engineered tumor infiltrating lymphocyte (TIL) cell therapies using its proprietary Co-Stimulatory Antigen Receptor (CoStAR) platform. Its lead candidate AXN-2510/IMM2510 is in Phase 1b/2 trials for advanced/metastatic non-small cell lung cancer, with additional Phase 1 studies in China exploring multiple solid tumor types.

Competitive Landscape

Pro stress-test →

Instil Bio competes in the CAR-T/TIL cell therapy space dominated by larger players like Novartis (Kymriah), Gilead (Yescarta), and emerging competitors like Iovance Biotherapeutics and Legend Biotech. TIL therapies represent a growing but smaller segment compared to CAR-T. Competitive advantages lie in CoStAR platform differentiation and FRA-targeting focus, though limited resources constrain development speed versus well-funded competitors.

Industry Context

Instil Bio, Inc. operates in Biopharmaceutical - Immunotherapy/Cell Therapy.

Key facts

Founded: 2018 · Headquarters: Dallas, United States · Employees: 14 · Market cap: $44.8M

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Instil Bio, Inc..

  • Proprietary CoStAR platform targeting folate receptor alpha for multiple solid tumors including ovarian, uterine, and lung cancers
  • Market cap severely compressed to $44.8M, indicating significant market skepticism
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • Jan 2026Stock trading significantly below 52-week highs amid clinical trial execution concerns
  • RecentPhase 1b/2 continuation for AXN-2510 in lung cancer with parallel China trials
  • +1 moreTrack every material event for Instil Bio, Inc. as it happens. Explore monitoring →
Get alerted when Instil Bio, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

KymriahCAR-T cell therapy for hematologic malignancies→YescartaCAR-T cell therapy for lymphomas→Afamitresgene AutoleucelTIL cell therapy for melanoma→

Compare Instil Bio, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Instil Bio, Inc. operates in Biopharmaceutical - Immunotherapy/Cell Therapy. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceutical - Immunotherapy/Cell Therapy research →
NEW · MCP server

Ask your AI assistant about Instil Bio, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Instil Bio, Inc. and its top competitor on Cyborg Score”
“What did Instil Bio, Inc. do this quarter?”
“Is Instil Bio, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Instil Bio, Inc. do?+
Instil Bio is a clinical-stage biopharmaceutical company developing a pipeline of cell therapies, specifically autologous tumor infiltrating lymphocyte (TIL) therapies for cancer treatment. The company was incorporate...
What is Instil Bio, Inc.'s Cyborg Score?+
Instil Bio, Inc. has a Cyborg Score of 3/10 (Weak). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Instil Bio, Inc.'s main competitors?+
Named competitors include Kymriah, Yescarta, Afamitresgene Autoleucel. The full competitive landscape is in the AskCyborg report.
How can I get the full Instil Bio, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Instil Bio, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Instil Bio, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biopharmaceutical - Immunotherapy research

Companies in the same sector and named competitors, ranked by Cyborg Score.

5XBiotech Inc.